Crizotinib for Non-Small Cell Lung Cancer
Study Summary
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
- Stage IIB Non-small Cell Lung Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer
- ALK Gene Rearrangement
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 207 Patients • NCT01639001Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What other efficacy studies have been done on Crizotinib?
"Crizotinib was first studied in 2007 at Surgical Intensive Care Unit Regional Hospital Jessa. As of now, there have been a total of 640 completed clinical trials. Out of these, 69 are active and ongoing, with a majority of these studies taking place in Canandaigua, New York."
Could you please elucidate the risks associated with Crizotinib?
"Crizotinib has been deemed safe by our team at Power. This is due to the fact that it is a Phase 3 trial, which means that there is some data to support its efficacy and multiple rounds of data that support its safety."
How many individuals are being included in this scientific research project?
"168 suitable patients are needed to fill the spots for this trial. Those who meet the requirements and live near one of the participating locations, such as Las Vegas Urology - Smoke Ranch in Canandaigua, New York or OptumCare Cancer Care at MountainView in Hendersonville, North Carolina, are encouraged to apply."
Are people needed for this clinical trial right now?
"That is correct. The online information from clinicaltrials.gov indicates that this research is still looking for 168 individuals from 100 different locations. The trial was originally posted on August 18th, 2014 with the most recent update happening on July 26th, 2022."
Does this clinical trial use any innovative or cutting-edge methods?
"As of now, there are 69 open clinical trials involving Crizotinib in 38 countries and 1221 cities. The very first trial was sponsored by Baxter Healthcare Corporation in 2007. That initial study had 4640 participants and successfully completed Phase 4 drug approval. Since that initial trial, there have been 640 more."
What are the FDA-approved indications for crizotinib?
"Crizotinib is the standard course of treatment for amino acid supplementation therapy. However, this medication can also be used to help patients with renal dysfunction, amino acid supplementation, and kidney failure."
Are there different hospitals in state conducting this research?
"Currently, patients are being enrolled at Las Vegas Urology - Smoke Ranch in Canandaigua, New York, OptumCare Cancer Care at MountainView in Hendersonville, North Carolina, and Sands Cancer Center in Belpre, Ohio. 100 other recruitment sites are also operational."